
Feb 18 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE
BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80
BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION
BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT
BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT